Wall Street Zen cut shares of HUTCHMED (NASDAQ:HCM – Free Report) from a strong-buy rating to a buy rating in a report issued on Saturday.
Separately, HSBC lowered HUTCHMED from a “buy” rating to a “hold” rating in a report on Tuesday, May 13th.
Read Our Latest Analysis on HCM
HUTCHMED Stock Down 4.6%
Institutional Investors Weigh In On HUTCHMED
Hedge funds have recently added to or reduced their stakes in the stock. Jane Street Group LLC grew its position in HUTCHMED by 128.0% during the first quarter. Jane Street Group LLC now owns 222,241 shares of the company’s stock valued at $3,343,000 after buying an additional 124,771 shares during the period. Goldman Sachs Group Inc. grew its holdings in HUTCHMED by 8.5% during the first quarter. Goldman Sachs Group Inc. now owns 93,919 shares of the company’s stock valued at $1,413,000 after purchasing an additional 7,342 shares during the period. Vident Advisory LLC grew its holdings in HUTCHMED by 78.3% during the first quarter. Vident Advisory LLC now owns 19,728 shares of the company’s stock valued at $297,000 after purchasing an additional 8,664 shares during the period. XY Capital Ltd raised its stake in shares of HUTCHMED by 142.4% in the first quarter. XY Capital Ltd now owns 113,136 shares of the company’s stock worth $1,702,000 after buying an additional 66,460 shares during the period. Finally, Crossmark Global Holdings Inc. raised its stake in shares of HUTCHMED by 31.4% in the first quarter. Crossmark Global Holdings Inc. now owns 24,420 shares of the company’s stock worth $367,000 after buying an additional 5,829 shares during the period. 8.82% of the stock is currently owned by hedge funds and other institutional investors.
About HUTCHMED
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
Featured Articles
- Five stocks we like better than HUTCHMED
- Trading Stocks: RSI and Why it’s Useful
- Synopsys Stock Falls on China Ban, But Long-Term Outlook Holds
- 3 Best Fintech Stocks for a Portfolio Boost
- Alphabet Enters a Bull Market: Is It Time to Buy?
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones
Receive News & Ratings for HUTCHMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHMED and related companies with MarketBeat.com's FREE daily email newsletter.